Objective To understand the microcystin(MC-LR)pollution in drinking water in the city and countryside of Fuling District,Sichuan,China.Methods In 2004,285 water samples were collected from different types of water in Fuling district in different season and the concentration of LR(MC-LR),total phosphorus and total nitrogen in water were determined respectively.Results From July to November in 2004,no LR(MC-LR)was detected and the total phosphorus and total nitrogen did not exceed the national standard limits in the drinking water in the city,but in the secondary water supply in the city,the MC-LR was detected,the total phosphorus and total nitrogen exceed the standard limits.In the countryside,the MC-LR was detected,the total phosphorus and total nitrogen exceed the standard limits.Conclusion In the countryside of Fuling District,Sichuan,China,the drinking water,water source and tap water,was seriously contaminated by microcystin,the total phosphorus and total nitrogen exceed the national standard limits.

Objective To evaluate the therapeutic efficacy and adverse reactions of raltitrexed plus oxaliplatin (RALOX project) and S1 in patients with advanced primary liver cancer.Methods Seventy-one patients with advanced primary liver cancer admitted to 6 cancer centers from July 2013 to July 2015 were divided into 2 groups according to the wishes of the patients and their families:RALOX group (34 patients) and S1 group (37 patients).The therapeutic efficacy such as objective remission rate (ORR),disease control rate (DCR),median overall survival (mOS),median progression free survival (mPFS),one year survival rate (SR),and adverse reactions in these patients were evaluated.Results Thirty-one patients could be evaluated in RALOX group,and 6 patients obtained partial response (PR),10 stable disease (SD) and 15 progressive disease (PD).Thirty-three patients could be evaluated in S1 group,and 3 patients obtained PR,8 patients SD and 22 PD.The ORR,DCR,and one year SR were 19.4％ vs.9.1％,51.6％ vs.33.3％,and 22.6％ vs.12.1％ respectively,and there were no statistically significant differences in the two groups (x2 =1.393,P =0.238;x2 =2.190,P =0.139;x2 =1.229,P =0.268).The mOS and mPFS were 7.2 months vs.6.1 months and 3.4 months vs.2.8 months,and there were statistically significant differences in the two groups (x2 =6.433,P =0.011;x2 =4.078,P =0.043).There was more serious peripheral nerve toxicity (29.0％ vs.3.0％,x2 =6.344,P =0.012) and lighter hand-foot syndrome (9.7％ vs.30.3％,x2 =4.201,P =0.040) in RALOX group than S1 group.But the incidences of other adverse effects were similar in the two groups.Condnsion RALOX project is safe and effective to the patients with advanced primary liver cancer.Compare with S1 project,RALOX project has better curative effects and the majority of adverse reactions are tolerable.The patients have good condition control and survival benefit.